Mammalian type I and II gonadotropin-releasing hormone (GnRH) receptors (GnRHRs) show differential ligand preference for
]GnRH-I but not [His 5 ]GnRH-I exhibit a higher potency in activating wild-type gmGnRHR-2 than native GnRH-I, indicating that amino acids at positions 7 and 8 of GnRHs are more important than position 5 for differential recognition by type I and type II GnRHRs. As a whole, these data suggest a molecular coevolution of ligands and their receptors and facilitate the understanding of the molecular interaction between GnRHs and their cognate receptors.
Gonadotropin-releasing hormone receptor (GnRHR), a rhodopsin-like G protein-coupled receptor (GPCR), is one of the most extensively studied receptors because of its dual significance both for understanding reproductive biology and for the development of medical therapies (Sealfon et al., 1997) . It is now well-established that most vertebrates, including human, have at least two forms of GnRH (White et al., 1998; Fernald and White, 1999) . One form, GnRH-I (also called mammalian GnRH), is primarily synthesized in the hypothalamus, whereas the other form, GnRH-II (also called chicken GnRH-II), is widely expressed in the brain and peripheral tissues. Although GnRH-I is known to regulate the secretion and synthesis of gonadotropins in the pituitary, the exact function of GnRH-II is largely unknown. The receptor for GnRH-I was first isolated from mammalian pituitary cells (Kaiser et al., 1992; Reinhart et al., 1992; Tsutsumi et al., 1992) and called mammalian type I GnRHR. Receptors that have a high affinity for GnRH-II have been identified in nonmammalian and mammalian species Illing et al., 1999; Millar et al., 2001; Neill et al., 2001; Wang et al., 2001; Bogerd et al., 2002; Seong et al., 2003) . Mammalian type II GnRHR is closer in structure to nonmammalian GnRHRs than mammalian type I GnRHR. Mammalian type II GnRHR, like nonmammalian GnRHRs, contains the intracellular C-terminal tail, which is functionally important for desensitization and internalization (Heding et al., 1998; Willars et al., 1999) , whereas mammalian type I GnRHR does not have a C-terminal tail. Mammalian type II and nonmammalian GnRHRs have Asp 2.50 and Asp 7.49 in the transmembrane helices (TMHs) 2 and 7, respectively, whereas mammalian type I GnRHRs contain Asp 2.50 and Asn 7.49 , which are known to be important for receptor conformation and signal transduction (Blomenröhr et al., 1997; Mitchell et al., 1998) .
Mammalian type II GnRHR has a higher affinity for GnRH-II than for GnRH-I, whereas the opposite is true for mammalian type I GnRHR. However, the factors that determine such differential ligand selectivity are poorly understood. Mutagenesis studies combined with computational modeling have identified a number of residues that are involved in ligand binding (Davidson et al., 1996; Flanagan et al., 2000; Hoffmann et al., 2000; Hövelmann et al., 2002) . GnRH-II differs from GnRH-I by three amino acids at positions 5, 7, and 8; thus, searching for residues that may interact with them would help us to understand the mechanism underlying differential ligand selectivity. It has been proposed that Tyr 5 and Leu 7 of GnRH-I interact with Tyr 6.58
and Trp 2.64 of mammalian type I GnRHR (Hövelmann et al., 2002) . However, because Tyr 6.58 and Trp 2.64 are also conserved in mammalian type II GnRHR, these residues alone cannot account for differential ligand selectivity. An acidic amino acid, Glu/Asp 7.32 in EL3 of mammalian type I GnRHR is known to confer ligand specificity for GnRH-I by an electrostatic interaction with Arg 8 of GnRH-I (Flanagan et al., 1994; Fromme et al., 2001) . However, this is not fully explanatory, because some nonmammalian GnRHRs have an acidic amino acid (e.g., Glu 7.32 for bfGnRHR-2 and Asp 7.32 for catfish GnRHR) at this homologous position, yet these receptors respond better to GnRH-II than to GnRH-I (Wang et al., 2001) . We have demonstrated that the positions of Ser and Pro flanking Glu/Asp 7.32 are critical determinants for ligand selectivity (Wang et al., 2004) . Replacement of the Ser-Glu-Pro (SEP) motif by Pro-Glu-Ser (PES) in mammalian type I GnRHR induced an increased sensitivity to GnRH-II but the opposite to GnRH-I. Moreover, mutation of a Ser-Gln-Ser (SQS) motif to SEP in bullfrog type I GnRHR (bfGnRHR-1) showed an increased sensitivity to GnRH-II but a decreased sensitivity to GnRH-I (Wang et al., 2004) . However, this study found no reverse-ligand selectivity when the Pro-Glu-Tyr (PEY) motif in bfGnRHR-2 was replaced by SEP, suggesting the involvement of other residues in ligand selectivity.
Sequence alignments showed that the EL3-proximal TMH7 of mammalian type II GnRHR has a high degree of sequence identity with that of nonmammalian GnRHRs but not with that of mammalian type I GnRHR. In the present study, using rat GnRHR and gmGnRHR-2 as models for representative mammalian type I and type II GnRHRs, respectively, we addressed whether EL3 and/or EL3-proximal TMH7 determine differential ligand selectivity. Domain swapping and site-directed mutagenesis studies suggest that the Pro-Pro-Ser (PPS) motif in EL3 and Leu 7.38 , Leu 7.43 , Ala 7.46 , and Pro 7.47 in TMH7 of gmGnRHR-2 are critical for discriminating GnRH-II from GnRH-I. AnyGen (Gwangju, Korea) . The c-fos-luc vector containing approximately Ϫ711 to ϩ45 sequence of the human c-fos promoter constructed in the pFLASH vector was a kind gift from Dr. R. Prywes (Columbia University, New York, NY). Vent DNA polymerase was purchased from New England Biolabs (Beverly, MA). All oligonucleotides were synthesized from GenoTech (Daejon, Korea). GH 3 cell lines stably expressing gmGnRHR-2 or rat GnRHR were established as described previously (Acharjee et al., 2002; Wang et al., 2003) .
Materials and Methods

Materials
Amino Acid Residue Numbering Scheme. Amino acid residues are numbered according to their positions in gmGnRHR-2. To facilitate the comparison among different GnRHRs, the standard numbering system proposed by Ballesteros and Weinstein (1995) was also used.
Construction of Wild-Type and Mutant GnRHRs. The cDNA of gmGnRHR-2 subcloned into pcDNA3 (Invitrogen, Carlsbad, CA) at the KpnI and XbaI sites was used as a template for creating domain-swapped or site-directed mutants. Domainswapping and site-directed mutagenesis were performed by the polymerase chain reaction overlapping-extension method (Wang et al., , 2004 . To facilitate the construction of domain-swapped mutants, an exogenously introduced EcoRV site at the Asn 7.34 residue and an intrinsic BstXI site or two intrinsic BamHI sites were used. EL3 or EL3-proximal TMH7 of rat GnRHR was amplified using a specific set of primers flanked by the overlapping sequence of gmGn-RHR-2 and the appropriate restriction endonuclease recognition site, producing rEL3S and rEL3L, respectively. The fragment from the N terminus to the EcoRV site at the Asn 7.34 residue of rEL3S was replaced by the corresponding fragment of rat GnRHR, generating the r6TM chimera. Likewise, the fragment from the N terminus to the BamHI site at the Pro 7.47 residue of gmGnRHR-2 was replaced by the corresponding part of rat GnRHR, producing the r6.5TM chimera. Mutated sequences were confirmed using the Sequenase Version 2.0 DNA Sequencing Kit (U.S. Biochemical Corporation, Cleveland, OH) according to the manufacturer's instructions.
Inositol Phosphate Production Assay. The inositol phosphate (IP) production assay was performed as described previously . GH 3 cells (1 ϫ 10 5 /well) expressing gmGnRHR-2 or rat GnRHR were seeded in 12-well plates, and the following day, cells were incubated in inositol-free DMEM (Invitrogen) containing 2% dialyzed fetal bovine serum and labeled with 1 Ci of [myo-3 H]inositol/well (Amersham Biosciences UK, Ltd., Little Chalfont, Buckinghamshire, UK) for 18 h. Medium was then removed, and cells were washed with 0.5 ml of buffer A (140 mM NaCl, 20 mM HEPES, 4 mM KCl, 8 mM D-glucose, 1 mM MgCl 2 , 1 mM CaCl 2 , and 1 mg/ml fatty acid-free BSA). Cells were then preincubated with buffer A containing 10 mM LiCl for 15 min, followed by treatment with graded concentrations (0.01 nM to 10 M) of GnRHs at 37°C for 45 min. The reaction was terminated by removing the incubation medium and adding 0.5 ml of ice-cold 10 mM formic acid. After 30 min at 4°C, the formic acid extracts were transferred into columns containing Dowex anion exchange resin. Total IPs were then eluted with 1 ml of 1 M ammonium formate/0.1 M formic acid, and their radioactivity was determined.
Luciferase Assay. Wild-type and mutant GnRHRs were transiently transfected into CV-1 cells, which were maintained at 37°C in DMEM with 10% heat-inactivated fetal bovine serum, 1 mM glutamate, 100 U of penicillin, and 100 g/ml streptomycin. Cells were seeded in 24-well plates (1 ϫ 10 5 /well), and transfection was performed using the SuperFect transfection kit (QIAGEN, Valencia, CA) according to the manufacturer's instructions with a minor modification. For each transfection, 100 ng of each receptor cDNA, 200 ng of c-fos-luc vector, and 200 ng of internal control plasmid pCMV␤-Gal were used. One day after transfection, cells were serum-starved for 24 h and then challenged with GnRH for 6 h . Cells were harvested, and luciferase activity in the cell extract was determined according to standard methods in a Lumat LB9501 (Berthold Technologies, Bad Wildbad, Germany). The luciferase activities were normalized using ␤-galactosidase values. Transfection experiments were performed in duplicate and were repeated three to five times.
Binding Assay. GnRH-II was radioiodinated using the chloramine-T method and purified by chromatography on a Sephadex G-25 (Sigma-Aldrich, St. Louis, MO) column in 0.01 M acetic acid and 0.1% BSA. HeLa cells were transfected with wild-type, individual mutant construct, or pcDNA3 (300 ng of DNA per well in 12-well plates) with Effectene (QIAGEN) according to the manufacturer's instructions. Thirty-six hours after transfection, intact cells were washed and incubated with binding buffer (DMEM supplemented with 0.1% BSA, pH 7.4) containing 250,000 cpm of 125 I-GnRH-II (0.5 ml final volume) at 20°C for 1 h to achieve equilibrium. Specific binding was calculated by subtracting nonspecific binding (the presence of 10 M unlabeled GnRH-II) from total binding. For the displacement binding assay, 125 I-GnRH-II was incubated in the presence of graded concentrations of unlabeled GnRH-I or GnRH-II.
Molecular Modeling. gmGnRHR-2 was built by MODELLER 6 version 2 (Sali and Blundell, 1993) on the basis of the crystal structure of bovine rhodopsin (Okada et al., 2002) as a template. GnRH-I or GnRH-II was docked onto putative binding sites of gmGnRHR-2 manually using Visual Molecular Dynamics (Humphrey et al., 1996) . The models for gmGnRHR-2/GnRH-II, mutant gmGnRHR-2/GnRH-I, and mutant gmGnRHR-2/GnRH-II were built by mutating corresponding residues in the gmGnRHR-2/GnRH-I model and underwent energy minimization and molecular dynamics annealing simulations in the MODELLER. The final models showing good geometry were confirmed by PROCHECK (Laskowski et al., 1993) . The contacts between ligands and receptors were analyzed using Ligplot (Wallace et al., 1995) . Figures of the models were drawn using Visual Molecular Dynamics (Humphrey et al., 1996) . Data Analysis. Analyses were performed using nonlinear regression, and the data were expressed as sigmoid dose-response curves. GnRH concentrations inducing half-maximal stimulation (EC 50 ), halfmaximal inhibition (IC 50 ), and maximal fold increases (E max ) were calculated using GraphPad Prism 3 software (GraphPad Software Inc., San Diego, CA). All data are presented as means Ϯ S.E.M. The data were analyzed by one-way analysis of variance followed by the Bonferroni test. A p value Ͻ0.05 was considered statistically significant.
Results
Differential Ligand Selectivity of Mammalian and
Nonmammalian GnRHRs. The ligand selectivities of rat GnRHR and gmGnRHR-2 were examined using two different methods: IP production, and c-fos promoter-driven luciferase (c-fos-luc) assays. For the IP assay, GH 3 cells stably expressing rat GnRHR or gmGnRHR-2 were used Maiti et al., 2003) , and for c-fos-luc assay, CV-1 cells transiently expressing rat GnRHR or gmGnRHR-2 were used. As for rat GnRHR, GnRH-I showed a lower EC 50 value than did GnRH-II, indicating that rat GnRHR has a higher sensitivity to GnRH-I than to GnRH-II. However, gmGnRHR-2 responded better to GnRH-II than did GnRH-I in both assay systems ( Fig. 1 and Table 1 ). Regarding GnRHR, GnRH-I had a 7.4-and 5.9-fold higher potency than GnRH-II in IP and c-fos-luc assay systems, respectively. For gmGnRHR-2, GnRH-II was 204-fold (IP assay) and 239-fold (c-fos-luc assay) more potent than GnRH-I (Table 1) . Because c-fos-luc was more sensitive than the IP assay system, we used the c-fos-luc system in ensuing experiments.
EL3 and EL3-Proximal TMH7 Are Involved in Differential Ligand Selectivity. Sequence alignment showed that EL3-proximal TMH7 of mammalian type II GnRHR has a high degree of sequence identity with that of nonmammalian GnRHRs but not mammalian type I GnRHR. Furthermore, it was suggested that the proximal region of TMH7 of GnRHR affects the conformation of EL3 (Petry et al., 2002) . We therefore presumed that both EL3 and the EL3-proximal TMH7 may be involved in differential ligand selectivity. To address this possibility, EL3 alone or together with EL3-proximal TMH7 of gmGnRHR-2 was swapped with that of rat GnRHR, designated rEL3S or rEL3L, respectively. Swapping EL3 alone did not induce a significant change in sensitivity for either GnRH-I or GnRH-II such that chimeric rEL3S, like Fig. 1 . Ligand selectivity of rat GnRHR or gmGnRHR-2. A, IP assays were performed using GH 3 cells which stably express rat GnRHR (rat) or gmGnRHR-2 (gm2). Cells were treated with increasing concentrations of GnRH-I or GnRH-II for 30 min. B, c-fos-luc activity was examined in CV-1 cells that were cotransfected with 200 ng of c-fos-luc reporter vector plus rat GnRHR or gmGnRHR-2. Twenty-four hours after transfection, cells were serum-starved for 18 h and then treated for 6 h with GnRH-I or GnRH-II. Cell lysates were used for luciferase assays. Broken lines are dose-responses of rat (E) and gm2 (F) to GnRH-I, and solid lines are dose-responses of rat (Ⅺ) and gm2 (f) to GnRH-II. wild-type gmGnRHR-2, showed a higher sensitivity to GnRH-II than to GnRH-I ( Fig. 2A) . It is interesting that rEL3L showed a great increase in sensitivity to GnRH-I but not to GnRH-II ( Fig. 2B and Table 2 ), indicating that EL3-proximal TMH7 in gmGnRHR-2 is probably important for the discrimination between them. The functional importance of EL3-proximal TMH7 was further confirmed by additional chimeric receptors that have N termini to EL3 or to EL3-proxmial TMH7 of rat GnRHR, denoted r6TM or r6.5TM, respectively. The chimeric receptor r6TM, which has the EL3-proximal TMH7 sequence of gmGnRHR-2, has a high sensitivity to GnRH-II and a low sensitivity to GnRH-I, characteristics of a type II receptor (Fig. 2C) . In contrast, r6.5TM containing the EL3-proximal TMH7 sequence of rat GnRHR has the ligand sensitivity, characteristic of a type I GnRHR (Fig. 2D) , again confirming that EL3-proximal TMH7 in gmGnRHR-2 is critical for ligand selectivity. Identification of rEL3L Amino Acids Involved in Ligand Selectivity. Because sequence alignment showed a six amino acid difference in EL3-proximal TMH7 between gmGnRHR-2 and rat GnRHR (Fig. 2E) , we postulated that one of them may be responsible for ligand selectivity. Thus, six individual amino acids were reciprocally changed in the rEL3L chimeric receptor. Point mutation of Phe 7.37 to isoleucine, Phe 7.38 to leucine, or Ala 7.42 to glycine did not induce significant changes in ligand selectivity compared with rEL3L (Fig. 3, A and B, and Table 2 ). Point mutation of Pro 7.46 to alanine or Cys 7.47 to proline completely suppressed receptor function in response to either GnRH-I or GnRH-II (Fig. 3, C and D) . Finally, the mutation of Phe 7.43 to leucine in rEL3L showed a significant decrease in sensitivity to GnRH-I (Fig. 3A) .
It was shown previously that Glu 7.32 of mouse GnRHR is a critical residue conferring ligand specificity for Arg 8 of GnRH-I (Flanagan et al., 1994) . Furthermore, we recently demonstrated that the positions of serine and proline flanking Glu 7.32 are crucial for the ligand selectivity between mammalian and nonmammalian GnRHRs (Wang et al., 2004) . Therefore, we sought to determine whether these amino acids are critical for the ligand selectivity in the chimeric receptor rEL3L. The Glu 7.32 or SEP motif in rEL3L was changed to glycine or PPS, respectively. A mutation of Glu 7.32 to glycine significantly decreased sensitivity to GnRH-I but not to GnRH-II (Fig. 3, C and D, and Table 2 ). Moreover, replacement of the SEP motif by PPS greatly increased sensitivity to GnRH-II, whereas it slightly decreased sensitivity to GnRH-I (Fig. 3, C and D, and Table 2 ). These results suggest that the SEP/PPS motif, together with amino acids in TMH7, is important in ligand sensitivity.
Identification of Amino Acids in Wild-Type gmGnRHR-2 That Confer Differential Ligand Selectivity. Because we observed that the amino acid residues Phe 7.43 , Pro 7.46 , and Cys 7.47 in rEL3L critically affected receptor activation and ligand selectivity, we further examined the function of these residues in wild-type gmGnRHR-2. Two mutants, L 7.43 F and A 7.46 P, had no receptor activity (Fig. 4 ). The mutant P 7.47 C had essentially the same ligand selectivity as the wild-type gmGnRHR-2 (Fig. 4) both GnRH-I and GnRH-II (Fig. 5, A and B) . The double mutant L 7.43 F/P 7.47 C showed a decrease in receptor efficacy in both GnRH-I and GnRH-II but showed a slight increase in sensitivity for GnRH-I (Fig. 5, A and B) . The double mutant L 7.43 F/A 7.46 P did not respond to GnRH stimulation (Fig. 5, A  and B) . A triple mutant, L 7.43 F/A 7.46 P/P 7.47 C, exhibited a large increase in ligand sensitivity for both GnRH-I and GnRH-II. Compared with wild-type gmGnRHR-2, the L 7.43 F/ Downloaded from A 7.46 P/P 7.47 C mutant showed a ϳ200-fold increased sensitivity to GnRH-I and a ϳ20-fold increased sensitivity to GnRH-II (Fig. 5, A and B) .
Because the PPS/SEP motif in EL3 and Leu 7.43 , Ala 7.46 , and Pro 7.47 residues in TMH7 affect ligand selectivity, we examined a combinatory effect of these two motifs. The gmGnRHR-2 with SEP/L 7.43 F/A 7.46 P/P 7.47 C mutation revealed a slight decrease in sensitivity for both GnRH-I and GnRH-II (Fig. 5, C and D) . This mutant also showed a decrease in E max values for both GnRHs compared with the L 7.43 F/A 7.46 P/P 7.47 C mutant, which may be caused by low receptor expression (Table 2 ). It is interesting that additional mutations rEL3S/L 7.43 F/A 7.46 P/P 7.47 C (Fig. 7B) , SEP/I 7.37 F/ L .38 F/L .43 F/A 7.46 P/P 7.47 C (Fig. 5, C and D) , or SEP/L 7.38 F/ L 7.43 F/A 7.46 P/P 7.47 C (Fig. 5 , C and D) increased sensitivity to GnRH-I and decreased sensitivity to GnRH-II (Table 2) .
Ligand Binding Affinities. Ligand affinities of wildtype, rEL3L, and SEP/L 7.38 F/L 7.43 F/A 7.46 P/P 7.47 C mutants were determined using a competition binding assay. For the binding assay, HeLa cells were used because when transfected with the receptors, they have a much higher binding capacity than CV-1 cells. It should be noted that HeLa cells, in the c-fos-luc assay system, produce EC 50 values similar to those of CV-1 cells when we applied the same receptor and ligand (data not shown). HeLa cells, however, have a high basal c-fos-luc activity; therefore, their fold increases are usually much lower than those in CV-1 cells . C mutants were Ϫ9.58 Ϯ 0.27, Ϫ10.19 Ϯ 0.23, and Ϫ9.96 Ϯ 0.27, respectively (Fig. 6B) , showing that ligand affinities for GnRH-II in mutant receptors do not change as drastically as those for GnRH-I.
Relative ligand binding of mutant constructs was determined using [
125 I]GnRH-II in the absence or presence of unlabeled GnRH-II (10 M). For wild-type gmGnRHR-2, total and nonspecific binding were 2.3 Ϯ 0.2% (5826 Ϯ 50 cpm) and 0.60 Ϯ 0.2% (1567 Ϯ 30 cpm), respectively. Total binding for other mutant receptors ranged from 1.16 to 6.83%, whereas nonspecific bindings for other receptors were the same as that for the wild-type receptor. Mutants that did not respond to GnRHs (rEL3L/P 313 A, rEL3L/C 314 P, L 7.43 F, and A 7.46 P) were unable to bind radioiodinated GnRH-II. rEL3S, L Table 3 ). This result supports the idea that positions 7 and 8 in GnRH are important for conferring its specificity.
Molecular Modeling. To support our biochemical data, we constructed models to simulate the interaction of GnRHs with wild-type gmGnRHR-2 and SEP/L 7.38 F/L 7.43 F/A 7.46 P/ P 7.47 C mutant (Fig. 8) . Overall, the models agree well with previous reports (Hövelmann et al., 2002; Wang et al., 2004) 
Discussion
The present study demonstrates that replacement of EL3 and EL3-proximal TMH7 of gmGnRHR-2 with those of rat GnRHR greatly improves ligand sensitivity to GnRH-I but not to GnRH-II. Site-directed mutations on gmGnRHR-2 and back mutations on the domain-swapped receptor show that the PPS motif in EL3 and Leu 7.38 , Leu 7.43 , Ala 7.46 , and Pro 7.47 in TMH7 of gmGnRHR-2 and the corresponding residues of rat GnRHR are responsible for differential ligand sensitivity to GnRH-I and GnRH-II.
It was suggested that not only Glu/Asp 7.32 but also the positions of Ser and Pro flanking Glu/Asp 7.32 in EL3 of mammalian type I GnRHR determine high selectivity for GnRH-I (Fromme et al., 2004; Wang et al., 2004) . These findings indicate that a local conformation of EL3 is critical for differential ligand selectivity among nonmammalian and mammalian types I and II GnRHRs. However, replacement of EL3 from gmGnRHR-2 alone does not affect ligand selectivity to GnRH-I and GnRH-II. Likewise, substitution of SEP for the PEY motif of bfGnRHR-2 does not alter ligand sensitivity to GnRH-I and GnRH-II (Wang et al., 2004) . These observations suggest that other amino acid residues/motifs are involved in the selectivity of GnRH. Our study strongly suggests that in mammalian type II GnRHR, EL3-proximal TMH7 in addition to EL3 participates in differential ligand selectivity. The importance of EL3-proximal TMH7 in ligand sensitivity is supported by the observation that rat GnRHR with the entire TMH7 of gmGnRHR-2 (r6TM) exhibits a significant decrease in sensitivity for GnRH-I. Mutations of Pro 7.47 to cysteine combined with the mutation of Leu 7.43 to phenylalanine and/or Ala 7.46 to proline significantly increases sensitivity for GnRH-I, whereas mutations of a single amino acid residue at these positions does not affect ligand selectivity to GnRH-I, suggesting that the combination of each amino acid in TMH7 is critical for differential ligand selectivity.
On the basis of Millar's classification , we aligned the sequences of EL3 and proximal TMH7 of various GnRHR subtypes: human-1 and rat-1 for mammalian type I receptors, green monkey-2 and marmoset-2 for type II mammalian receptors, bullfrog-3 and Xenopus-2 for nonmammalian type II receptors, Japanese medaka-1 and bullfrog-2 for type III receptors, and finally Japanese medaka-2, bullfrog-2, and catfish-1 for nonmammalian type I receptors. Leu 7.40 , Leu 7.44 , and Asn 7.45 residues are con- served between gmGnRHR-2 and the mammalian type I receptors, but these residues are also largely conserved in many other nonmammalian GnRHRs. Thus, these amino acid residues are not specific to mammalian GnRHR subtypes. After excluding the amino acids that are conserved throughout the GnRHR subtypes, we found that at least four residues, Iso 7.37 , Leu 7.38 , Gly 7.42 , and Leu 7.43 , in gmGn-RHR-2 are different from those in mammalian type I receptors but are highly conserved in nonmammalian GnRHRs (Fig. 9 ). Among these, Iso 7.37 and Gly 7.42 are not likely to contribute to GnRH-I selectivity, because back-mutations of these residues in the rEL3L receptor did not significantly affect sensitivity to GnRH-I. Two amino acids, Ala in TMH7 significantly increase ligand sensitivity to GnRH-I. We cannot explain clearly how the combined mutation L 7.38 F/A 7.46 P/P 7.47 C increases GnRH-I sensitivity. It is unlikely that these residues have direct interactions with GnRH-I because they are deeply buried in the three-dimensional structure. Rather, the mutation on these residues may play a role in modulating conformation of the binding pocket Fig. 8 . Molecular models for the interaction of GnRH-II with wild-type gmGnRHR-2 (A), GnRH-I with wild-type gmGnRHR-2 (B), GnRH-II with the SEP/L
